News Breaks |
|
|
| February 8, 2013 |
| 09:37 EDT |  | TCK, IRG, PLD, THOR, PNG, IT, CFN, NUAN, CMI, TEVA, ANR, OSK, CYS, SKUL, DE, BG, RVBD, ITW | On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Alpha Natural (ANR) downgraded to Fair Value from Buy at CRT Capital... Riverbed (RVBD) downgraded to Market Perform from Outperform at FBR Capital... Skullcandy (SKUL) downgraded to Neutral from Buy at Roth Capital... Teva (TEVA) downgraded to Hold from Buy at Canaccord... Bunge (BG) downgraded to Hold from Strong Buy at Feltl... CYS Investments (CYS) downgraded to Neutral from Buy at Compass Point... Deere (DE) downgraded to Buy from Strong Buy at ISI Group... Cummins (CMI) downgraded to Buy from Strong Buy at ISI Group.. Oshkosh (OSK) downgraded to Buy from Strong Buy at ISI Group... Illinois Tool Works (ITW) downgraded to Buy from Strong Buy at ISI Group... Gartner (IT) downgraded to Neutral from Overweight at Piper Jaffray... ProLogis (PLD) downgraded to Hold from Buy at Stifel Nicolaus... Nuance (NUAN) downgraded to Hold from Buy at Stifel Nicolaus... CYS Investments (CYS) downgraded to Hold from Buy at Stifel Nicolaus... PAA Natural Gas Storage (PNG) downgraded to Market Perform from Outperform at Raymond James... Ignite Restaurant (IRG) downgraded to Outperform from Strong Buy at Raymond James... CareFusion (CFN) downgraded to Outperform from Buy at CLSA... Riverbed (RVBD) downgraded to Neutral from Buy at Lazard Capital... Thoratec (THOR) downgraded to Market Perform from Outperform at Northland Securities... Teck Resources (TCK) downgraded to Neutral from Overweight at JPMorgan. |
|
|
News For ANR;RVBD;SKUL;TEVA;BG;CYS;CMI;DE;OSK;ITW;IT;PLD;NUAN;PNG;IRG;CFN;THOR;TCK From The Last 14 Days Check below for free stories on ANR;RVBD;SKUL;TEVA;BG;CYS;CMI;DE;OSK;ITW;IT;PLD;NUAN;PNG;IRG;CFN;THOR;TCK the last two weeks. |
|
|
| May 13, 2013 |
| 09:44 EDT |  | TEVA | Several companies reportedly interested in buying Adcock Ingram, Globes says
 Subscribe for More Information |
|
| 07:49 EDT |  | TEVA | FDA decision on Opana a modest positive for Impax, says Leerink
Leerink views the FDA's denial of Endo's (ENDP) Citizen Petition as a modest positive for Impax (IPXL), which it notes is the sole holder of 180 day exclusivity on generic Opana. However, Leerink says upside for Impax will be limited as Actavis (ACT), Sandoz, and Teva (TEVA) have settlements to enter the market starting in June 2013 when Impax's 180-day generic exclusivity expires. |
|
| 07:31 EDT | | THOR | Thoratec downgraded to Neutral from Buy at Lazard Capital
Subscribe for More Information |
|
| 07:19 EDT |  | CYS | JMP Securities to host a conference
Subscribe for More Information |
|
| May 10, 2013 |
| 10:38 EDT |  | NUAN | Rumor: Nuance moves up on renewed takeover chatter
|
|
| 10:00 EDT |  | NUAN, TEVA | On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 3D Systems (DDD) initiated with a Buy at Janney Capital... Actavis (ACT) initiated with an Outperform at BMO Capital... Allergan (AGN) initiated with an Outperform at BMO Capital... Emeritus (ESC) initiated with an Outperform at Wells Fargo... Ensign Group (ENSG) initiated with a Market Perform at Wells Fargo... Forest Labs (FRX) initiated with an Underperform at BMO Capital... J2 Global (JCOM) initiated with an Outperform at Wedbush... Mylan (MYL) initiated with an Underperform at BMO Capital... Splunk (SPLK) initiated with a Market Perform at FBR Capital... Teva (TEVA) initiated with an Outperform at BMO Capital... Workday (WDAY) initiated with an Outperform at Oppenheimer... Nuance (NUAN) initiated with an Outperform at Wedbush... Demandware (DWRE) initiated with an Outperform at Wedbush... Synchronoss (SNCR) initiated with an Outperform at Wedbush... Trius Therapeutics (TSRX) initiated with a Buy at Guggenheim... Proto Labs (PRLB) initiated with a Buy at Janney Capital... Stratasys (SSYS) initiated with a Buy at Janney Capital. |
|
| 08:43 EDT | | NUAN | Nuance initiated with an Outperform at Wedbush
Subscribe for More Information |
|
| May 9, 2013 |
| 16:35 EDT | | TEVA | Teva initiated with an Outperform at BMO Capital
Subscribe for More Information |
|
| 16:15 EDT |  | CFN | CareFusion affirms FY13 adjusted EPS view $2.11-$2.21, consensus $2.15
Subscribe for More Information |
|
| 16:13 EDT | | CFN | CareFusion reports Q3 adjusted EPS 59c, consensus 53c
Subscribe for More Information |
| |
| 15:27 EDT | | CFN | Notable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include priceline.com (PCLN), consensus $5.27; Public Storage (PSA), consensus $1.62; NVIDIA (NVDA), consensus 10c; CareFusion (CFN), consensus 53c; Assured Guaranty (AGO), consensus 68c; Medivation (MDVN), consensus (41c); Great Plains Energy (GXP), consensus 12c; Salix Pharmaceuticals (SLXP), consensus 68c; Air Lease (AL), consensus 38c; Sotheby's (BID), consensus (12c). |
|
| 11:35 EDT |  | ANR | Kansas City Southern says coal volumes are up 5% in Q2
On its presentation at the Wells Fargo conference the CFO said that coal volumes are up approximately 5% in Q2. |
|
| 09:20 EDT | | ITW | Hardinge to acquire Forkardt Operations from Illinois Tool Works for $34M
Subscribe for More Information |
|
| 07:37 EDT | | PNG | PAA Natural Gas Storage downgraded to Underperform from Neutral at BofA/Merrill
|
|
| May 8, 2013 |
| 12:03 EDT | | TEVA | Teva says data demonstrates ovulatory effect of investigational contraceptive
Subscribe for More Information |
|
| 10:57 EDT | | CFN | ICU Medical jumps after report says company considering sale
Subscribe for More Information |
|
| 10:26 EDT | | TEVA | Alexza deal with Teva could be worth $12 per share or more, says Roth Capital
Subscribe for More Information |
|
| 09:06 EDT | | TEVA | Alexza Pharmaceuticals to host conference call
Subscribe for More Information |
|
| 08:33 EDT | | TEVA | Teva, Alexza announce Teva's license to market Adasuve in the U.S.
Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical (TEVA), and Alexza Pharmaceuticals (ALXA) announced that the companies have entered into an exclusive U.S. license and supply agreement for Adasuve inhalation powder 10 mg for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Teva will be responsible for all U.S. commercial and clinical activities for Adasuve, including U.S. post-approval clinical studies, and has gained rights to conduct additional clinical trials of Adasuve for potential new indications in neurological disorders. Alexza will be responsible for manufacturing and supplying Adasuve to Teva for commercial sales and clinical trials. Under the terms of the license and supply agreement, Alexza will receive an upfront cash payment of $40M and is eligible to receive up to $195M in additional milestone payments, based upon successful completion of the ADASUVE post-approval studies in the U.S. and achieving net sales targets. In addition, Teva will make tiered, royalty payments based on net commercial sales of Adasuve. |
|
| 05:52 EDT |  | ANR | Stocks with implied volatility movement; ARNA ANR
Stocks with implied volatility movement; Arena Pharmaceuticals (ARNA), Alpha Natural (ANR) according to IVolatility. |
| |
|
|
|
|
